Interpace Biosciences Profit Margin

Interpace Biosciences's profit margin stands at 65.25% as of March 2026. That compares with 16.36% in the prior-year period — up 298.8% year over year. That is above the sector sector average of 19.61%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Interpace Biosciences reported 65.25% in profit margin versus 16.36% a year earlier — a 298.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Interpace Biosciences sits higher the its sector benchmark (19.61%) with a profit margin of 65.25%. That is roughly 232.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 65.25% for Interpace Biosciences means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Interpace Biosciences's profit margin evolved across reporting periods, while the comparison chart places IDXG next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.